Kinaction (masitinib) / AB Science  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinaction (masitinib) / AB Science
2010-022793-14: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma.

Not yet recruiting
2
57
Europe
masitinib, Irinotecan, AB1010, Film-coated tablet, Solution for infusion, Irinotecan/Campto®/Camptosar®
AB Science
gastric or gastro-oesophageal junction metastatic adenocarcinoma
 
 
2010-020603-79: Evaluation of masitinib in acute ischemic stroke Evaluación de masitinib en pacientes con ictus isquémico agudo

Ongoing
2
45
Europe
masitinib, AB1010 tablets,
AB Science, ABScience
patients suffering from Acute Ischemic Stroke Pacientes con ictus isquémico agudo
 
 
2012-005586-13: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)

Ongoing
2
30
Europe
MASITINIB, AB1010,
AB SCIENCE, AB Science, AB SCIENCE, AB Science
Patients with severe COPD Pacientes con EPOC grave
 
 
2021-005406-96: A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment

Not yet recruiting
2
78
Europe
AB1010 Tablets, AB1010 Tablets, Film-coated tablet
AB Science, AB Science
severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment, severe mast cell activation syndrome (MCAS), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04622865 / 2020-001635-27: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Recruiting
2
200
Europe
Masitinib, AB1010, Isoquercetin, quercetin-3-O-glucoside, isotrifoliin, Best Supportive Care, BSC
AB Science
SARS-CoV 2, COVID-19, Coronavirus Disease 2019
12/23
12/23
NCT05047783: Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Recruiting
2
78
Europe, RoW
Masitinib Mesylate, Masitinib, AB1010, Placebo
AB Science
Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
12/23
12/23
NCT05449444: Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Recruiting
2
72
Europe, US
Masitinib 4.5 mg/kg/day, AB1010, Placebo, Placebo Oral Tablet, Best supportive care, BSC, Masitinib 6.0 mg/kg/day
AB Science
Mast Cell Activation Syndrome
12/24
12/24
2010-022620-77: Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancer Evaluación de la seguridad y eficacia de masitinib combinada con etopósido o irinotecán en pacientes con cáncer de hígado recurrente

Ongoing
1/2
36
Europe
masitinib, etoposide, irinotecan, AB1010, Film-coated tablet, Solution for infusion, Solution for injection, Toposar®, VePesid®, Etopophos®, Camptosar
AB Science, , AB Science
hepatocellular carcinoma, Hepatic cancer Cáncer de Hígado, Diseases [C] - Cancer [C04]
 
 

Download Options